⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
XBIO News
Xenetic Biosciences, Inc.
Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma
accessnewswire.com
XBIO
Form 8-K
sec.gov
XBIO
Form 8-K
sec.gov
XBIO
Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics
accessnewswire.com
XBIO
Xenetic Biosciences y Santersus AG acuerdan crear un líder global en terapias contra las NET
accessnewswire.com
XBIO
Xenetic Biosciences und Santersus AG geben endgültige Vereinbarung über einen Aktientausch bekannt, um einen weltweit führenden Anbieter von auf NETs ausgerichteten Therapeutika zu schaffen
accessnewswire.com
XBIO
Form 8-K
sec.gov
XBIO
Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform
accessnewswire.com
XBIO
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
accessnewswire.com
XBIO
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
accessnewswire.com
XBIO